



21 March 2017

GlaxoSmithKline Pte Ltd  
150 Beach Road,  
#22-00 Gateway West,  
Singapore 189720

T +65 6232 8338  
F +65 6392 5972  
www.gsk.com

**By Courier, Fax and Email**


1. The BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400 001  
Tel No.: +91 22 2272 1233/ 4  
Fax No: +91 22 2272 3121  
Email: corp.relations@bseindia.com
2. National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051  
Tel No: (022) 26598100 - 8114  
Fax No: (022) 26598120  
Email: takeover@nse.co.in

Dear Sirs,

**Re: Disclosures under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

This is to inform you that we, GlaxoSmithKline Pte Ltd, having our registered office at 150 Beach Road, #21-00, Gateway West, Singapore 189720, are addressing this letter to you for the purpose of disclosing the proposed acquisition of 31,92,238 equity shares held by Castleon Investment Ltd., Mauritius in GlaxoSmithKline Pharmaceuticals Limited which is listed on the BSE Limited and the National Stock Exchange of India Limited. We are enclosing herewith the Form for disclosure of details of the proposed acquisition of equity shares in terms of Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Yours faithfully,  
For GlaxoSmithKline Pte Ltd


  
Authorised Signatory  
(Jason Nicholas Masi, Director)

Encl: a/a

**Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

1.	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited
2.	Name of the acquirer (s)	GlaxoSmithKline Pte Ltd
3.	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters.	The acquirer forms part of the promoter and promoter group
4.	Details of the proposed acquisition	
	a. Name of the person(s) from whom shares are to be acquired	Castleton Investment Ltd
	b. Proposed date of acquisition	28 March 2017
	c. Number of shares to be acquired from each person mentioned in 4(a) above	31,92,238
	d. Total shares to be acquired as % of share capital of TC	3.77%
	e. Price at which shares are proposed to be acquired	Approximately INR 2,750 <b>Note:</b> the price set out above is on the basis of the closing share price applicable on the last working day prior to the date of this filing and could be subject to minor changes as the acquisition price will be set as the closing share price two days prior to the transfer date
	f. Rationale, if any, for the proposed transfer	Inter-se transfer between promoter & promoter group
5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer.	Regulation 10(1)(a)(iii)
6.	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	INR 2,711
7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	N.A.
8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	The acquisition price is not higher by more than 25% of the price computed in point 6 above.
9.	i. Declaration by the acquirer, that the transferor and transferee have complied (during 3 years prior to the date of proposed acquisition)/will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011	i. The acquirer hereby confirms that the transferor and the transferee have complied (during 3 years prior to the date of proposed acquisition) and will comply, with the applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011.  ii. Please see enclosed the copies of the disclosures made by the transferor and the transferee during the previous

Authorised Signatory  
 (Person Nicholas Masi, Director)  
 GlaxoSmithKline Pte Ltd  
 Date : 21 March 2017  
 Place : Singapore



Note: (\*) Shareholding of each entity may be shown separately and then collectively in a group. The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

		10.		11.			
		The acquirer hereby confirms that all the conditions specified under regulation 10(1)(a) of the Takeover Regulations, 2011 with respect to exemptions have been duly complied with.		Shareholding details			
		Before the proposed transaction		After the proposed transaction			
		No. of shares/ % w.r.t total share voting rights	No. of shares/ % w.r.t total share voting rights	No. of shares/ % w.r.t total share voting rights	No. of shares/ % w.r.t total share voting rights		
ii. The aforesaid disclosures made during previous 3 years prior to the date of proposed acquisition to be furnished.  (corresponding provisions of the repealed Takeover Regulations 1997) terms of Chapter V of the Takeover Regulations, 2011.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Acquirer(s) and PACs (other than sellers) (*)	(i) Glaxo Group Ltd.	3,04,85,250	35.99%	3,04,85,250	35.99%
			(ii) GlaxoSmithKline Pte Ltd. (Acquirer)	2,06,09,774	24.33%	2,38,02,012	28.10%
			(iii) Eskaylab Ltd.	58,80,000	6.94%	58,80,000	6.94%
			(iv) Burroughs Welcome International Ltd.	33,60,000	3.97%	33,60,000	3.97%
			<b>Total of (a):</b>	<b>6,03,35,024</b>	<b>71.23%</b>	<b>6,35,27,262</b>	<b>75%</b>
			b. Seller (s)	31,92,238	3.77%	NIL	NIL
		Castleton Investment Ltd					



Corporate Identity Number  
CIN: 272495 GSKL  
E-mail: [info@glaxosmithkline.com](mailto:info@glaxosmithkline.com)  
Web: [www.glaxosmithkline.com](http://www.glaxosmithkline.com)

Encl:

Alay Nadkarni  
General Manager - Administration  
& Company Secretary

*Alay Nadkarni*

Yours faithfully  
GlaxoSmithKline Pharmaceuticals Limited

Thanking you,

We hope the same is in order.

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte. Limited, Ekayard Limited, Birmingham Wellcome International Limited and Castleon Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2014.

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

BOMBAY STOCK EXCHANGE LIMITED  
PILROZE JEEJEBHOY TOWERS  
DALAL STREET  
MUMBAI  
400001

4<sup>th</sup> April 2014

Regd. Office: 22, 24th Floor,  
West, Mumbai - 400200  
Fax: 01 22 2403 5497

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: 22, 24th Floor,  
West, Mumbai - 400200



Pre-Joint - 2014 - to BSE



Corporate Identity Number  
L22304G110247L0201103  
Email: info@glaxosmithkline.com  
www.ghk.in

Encl:

Ajay Nadkarni  
General Manager - Administration  
& Company Secretary

GlaxoSmithKline Pharmaceuticals Limited  
Thanking you,  
Yours faithfully

We hope the same is in order.

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eckaylab Limited, Burroughs Wellcome International Limited and Casleton Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2014.

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

NATIONAL STOCK EXCHANGE  
EXCHANGE PLAZA, 5<sup>TH</sup> FLOOR,  
PLOT No. C/1, G BLOCK,  
BANDRA-KARVEA COMPLEX,  
BANDRA (EAST), MUMBAI  
400081

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Annie Besant Road,  
Worli, Mumbai - 400030.  
Tel: +91 22 2495 9595  
Fax: +91 22 2495 9494



GlaxoSmithKline

NSE

PRE DOWN - 2014 - 10 NSE

4<sup>th</sup> April 2014

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	2. Name(s) of the stock exchange(s) where the shares of the TC are listed	3. Particulars of the shareholder(s): a) Name of person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. b) Name(s) of promoter(s), member of the promoter group and PAC with him.	4. Particulars of the shareholding of persons(s) mentioned at (3) above	As of March 31st of the year, holding of:		Total	
				a) Shares	b) Voting Rights (other than by shares)	c) Warrants	
				d) Convertible Securities	e) Any other instrument that would entitle the holder to receive shares in the TC.		
GlaxoSmithKline Pharmaceuticals Limited	National Stock Exchange, BSE	Glaxo Group Limited GlaxoSmithKline Pte Limited EsKayob Limited Burrourghs Wellcome International Limited Cashdon Investment Limited	Number of shares % w.r.t. total share % of total share/voting of TC (*) Divided capital	63527262 75% 75% 84703017	63527262 75% 75% 84703017	- - - -	- - - -

(\*) Divided share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.


Signature of the Authorized Signatory:

Date: 1 April 2014  
 For and on behalf of  
 The Promoter  
 GlaxoSmithKline Pharmaceuticals Limited  
 Placet: England



GlaxoSmithKline Pte Ltd  
Company No. 19802938K

Authorized signatory



For GlaxoSmithKline Pte Ltd,

Yours faithfully

Thanking You,

The above is for your information and records.

Enclosed is the report in the format as prescribed by Securities and Exchange Board of India.

In compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI Takeover Regulations"), we are hereby notifying the information regarding our acquisition of 20,609,774 equity shares of GlaxoSmithKline Pharmaceuticals Limited, on 10 March 2014. As required under Regulation 29(3) of the SEBI Takeover Regulations, we are informing you about the said acquisition within 2 working days of the acquisition of share in the Company.

Sub: Filing of report under Regulation 29(1) of the SEBI Takeover Regulations.

Dear Sir / Madam

The Managing Director  
National Stock Exchange of India  
Limited  
Exchange Plaza  
Plot No. C/1, G Block  
Bandra Kurla Complex  
Bandra (East)  
Mumbai 400 051

The Managing Director  
BSB Limited  
PJ Towers  
Mumbai-400 001

To,  
GlaxoSmithKline  
Pharmaceuticals Limited

12 March 2014

Filing under SEBI Takeover Regulations

GlaxoSmithKline Pte Ltd  
150 Beach Road  
#22-00 Gateway West  
Singapore 189720  
Tel: +65 6232 8338  
www.gsk.com

GlaxoSmithKline



GlaxoSmithKline Pte Ltd  
Company No. 198192938K

1.	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer.	Acquirer - GlaxoSmithKline Pte Ltd PAC 1 - GlaxoSmithKline pte PAC 2 - Glinxo Group Limited
3.	Whether the acquirer belongs to Promoter/Promoter group	Yes
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited BSE Limited
5.	Details of the acquisition of shares/voting rights/holding of the Acquirer and the PAC	Number % w.r.t. total share/voting capital wherever applicable TC (*) share/voting capital of the TC (*)
	Before the acquisition under consideration, holding of:	(a) Shares carrying voting rights
	Acquirer - Nil	PAC 1- Nil PAC 2- 30,485,250 Other Promoter Entities - 12,432,238
	Acquirer- Nil	PAC 1- Nil PAC 2- 35.99% Other Promoter Entities - 14.68%
	Acquirer- Nil	PAC 1- Nil PAC 2- 35.99% Other Promoter Entities - 14.68%

**Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

GlaxoSmithKline Pte Ltd  
150 Beach Road  
#22-00 Gateway West  
Singapore 109720  
Tel. +65 6232 0330  
www.gsk.com








Place: Singapore  
Date: 13 March 2017

Authorized Signatory



For GlassSmithKline Plc Ltd

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Notes:

10.	Total diluted share/voting capital of the TC after the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares
9.	Equity share capital/total voting capital of the TC after the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares
8.	Equity share capital/total voting capital of the TC before the said acquisition.	The issued and subscribed share capital of the TC is INR 847,030,170 (Indian Rupees Eight Hundred Forty Seven Million Thirty Thousand and Seventy only) consisting of 84,703,017 fully paid up equity shares

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठा और विनिमय बोर्ड**

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s):	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.		
	a. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
	b. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share/voting capital whereever applicable (*)	% of total diluted share/voting capital of TC
	As of March 31st of the year, holding of:	20609774	24.33	24.33
	a) Shares			
	b) Voting Rights (otherwise than by shares)			
	c) Warrants,			
	d) Convertible Securities			
	d) Any other instrument that would entitle the holder to receive shares in the TC.			
	Total	20609774	24.33	24.33

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठा और विनिमय बोर्ड**

779 APR 2015  
 35 HK  
 WORK ADMINISTRATION

File - 2015 - 52 Company

Note: 1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.  
 (\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.  
 (\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Signature of the Authorized Signatory



Date: 2 April 2017

Place: Singapore

Name(s) of the person and Persons Acting in Concert		
(PAC) with the person		
Whether the person belongs to Promoter / Promoter group		Promoter
PAN of the person and PACs		
Name of the Target Company		Glaxosmithkline Pte Ltd
Name of the Target Company		Glaxosmithkline Pharmaceuticals Limited

Part-B\*\*

Corporate Identity Number  
L34239MH1024PLC001161  
Email id: askus@gsk.com  
Web site address: www.gsk.in/gsk.com

Encl:

Ajay Narkani  
General Manager - Administration  
& Company Secretary

*Ajay Narkani*

Yours faithfully  
GlaxoSmithKline Pharmaceuticals Limited

Thanking you,

We hope the same is in order.

Company as on 31<sup>st</sup> March 2015.  
International Limited and Castleion Investment Limited in respect of their shareholding in our  
Group Limited, GlaxoSmithKline Pte Limited, Ekaylab Limited, Burroughs Wellcome  
Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your  
Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

NATIONAL STOCK EXCHANGE,  
EXCHANGE PLAZA, 6<sup>TH</sup> FLOOR,  
PLOT No. 0/1, G BLOCK,  
BANDRA KURLA COMPLEX,  
BANDRA (EAST), -MUMBAI -  
400051

8<sup>th</sup> April 2015

Tel: +91 22 2495 9595  
Fax: +91 22 2495 9494

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Amle Road,  
Vashi, Mumbai - 400030.

GlaxoSmithKline







1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited	
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3	Particulars of the shareholder(s) :		
a.	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	or Name(s) of promoter(s), member of the promoter group and PAC with him.	
b.	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share/voting share/voting diluted share/voting capital of TC wherever applicable (*)
As of March 31st of the year, holding of:			
a) Shares		3192238	3.77
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
d) Any other instrument that would entitle the holder to receive shares in the TC.			
Total		3192238	3.77

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1





Part-B\*\*

Name of the Target Company: GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	

Signature of the Authorised Signatory

*[Handwritten Signature]*

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठा और विनिमय बोर्ड**

1 Name of the Target Company (TC)		Glaxosmithkline Pharmaceuticals Limited	
2 Name(s) of the stock exchange(s) where the shares of the TC are listed		Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3 Particulars of the shareholder(s) :			
a. Name of person(s) together with Person(s) Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.		Glaxosmithkline Pte Ltd.	
b. Name(s) of promoter(s), member of the promoter group and PAC with him.			
Particulars of the shareholding of person(s) mentioned at (3) above		Number of shares	
% of total		% w.r.t. total	
diluted share/voting share/voting capital		share/voting capital	
wherever applicable (*)		wherever applicable	
capital of TC		capital of TC	
As of March 31st of the year, holding of:		As of March 31st of the year, holding of:	
a) Shares		20609774	
b) Voting-Rights (other than by-shares)		24.33	
c) Warrants,			
d) Convertible Securities			
d) Any other instrument that would entitle the holder to receive shares in the TC			
Total		24.33	

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठा और विनिमय बोर्ड**

27 APR 2015  
 SSK

Part-B\*\*

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	

Signature of the Authorized Signatory

Place:

Singapore

Date:

3 April 2017

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Corporate Identity Number  
L24299MH1924PL000101  
Email ID: sekhu@skh.com  
Web site address: www.gsk.com

Thanking you,  
Sincerely faithfully,  
Ajay Nadekar  
General Manager - Administration  
& Company Secretary  
GlaxoSmithKline Pharmaceuticals Limited

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011  
Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your  
Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo  
Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome  
International Limited and Castleon Investment Limited in respect of their shareholding in our  
Company as on 31<sup>st</sup> March 2015.  
We hope the same is in order.

Dear Sir,  
BOMBAY STOCK EXCHANGE LIMITED  
PHIROZE JEEJEBHOY TOWERS  
DALAL STREET  
MUMBAI  
400001

6<sup>th</sup> April 2015  
Tel: +91-22-2495-9897  
Fax: +91-22-2495-0494  
GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Amde Bexani Road,  
Worli, Mumbai - 400030.



GlaxoSmithKline

2015  
Pte - 30111 - 10111 - 10111

Part-A: Details of Shareholding			
1	Name of the Target Company (TC)	GloxosmithKline Pharmaceuticals Limited	
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange ; BSE National Stock Exchange, NSE	
3	Particulars of the shareholder(s) :		
4	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	or	
		Name(s) of promoter(s), member of the promoter group and PAC with him. Castleton Investment Limited	
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	
		% w.r.t. total share/voting capital	
As of March 31st of the year, holding of:	a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities	3192238	3.77
		3192238	3.77
d) Any other instrument that would entitle the holder to receive shares in the TC.	Total	3192238	3.77
			3.77

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1




**भारतीय प्रतिष्ठान और विनिमय बोर्ड**  
**Securities and Exchange Board of India**

Part-B\*\*

Name of the Target Company **GlaxoSmithKline Pharmaceuticals Limited**

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory



Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

**SEBI** भारतीय प्रभुत्व और विनिमय बोर्ड  
**Securities and Exchange Board of India**

1 Name of the Target Company (TC)		GlaxoSmithKline Pharmaceuticals Limited	
2 Name(s) of the stock exchange(s) where the shares of the TC are listed		Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3 Particulars of the shareholder(s):			
a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.		GlaxoSmithKline Pte Ltd	
b. Name(s) of promoter(s), member of the promoter group and PAC with him or			
4 Particulars of the shareholding of person(s) mentioned at (3) above			
As of March 31st of the year, holding of:			
a) Shares	20609774	24.33	24.33
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
Any other instrument that would entitle the holder to receive shares in the TC.			
Total	20609774	24.33	24.33

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1

**SEBI** भारतीय प्रभुत्व और विनिमय बोर्ड  
**Securities and Exchange Board of India**

SEBI  
 77 D APR 2015



1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Note:

Date:

Place:

Signature of the Authorized Signatory



Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter Group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	

Name of the Target Company: GlaxoSmithKline Pharmaceuticals Limited

Part-B\*\*

1. Name of the Target Company (TC)		2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed		3. Particulars of the shareholder(s):		4. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.		5. Name(s) of promoter(s), member of the promoter group and PAC with him.		6. Particulars of the shareholding of person(s) mentioned at (3) above		7. As on March 31 <sup>st</sup> of the year 2016, holding of:		Total	
GlaxoSmithKline Pharmaceuticals Limited		Bombay Stock Exchange, BSE National Stock Exchange, NSE						GlaxoSmithKline Pte Ltd		Number of shares		a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.			
				% of total		% w.r.t. total				diluted		As on March 31 <sup>st</sup> of the year 2016, holding of:			
				share/voting capital wherever applicable (*)		share/voting capital wherever applicable				share/voting capital of TC		a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.			
				24.33		24.33		2,06,09,774		2,06,09,774		24.33		24.33	

Part-A- Details of Shareholding

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


Part - 2016 - to Company

Part-B\*\*

Name of the Target Company:

Name(s) of the person and Persons Acting in Concert	Whether the person belongs to Promoter/Promoter group	Whether the person belongs to PAN of the person and PACs
Glaxosmithkline Pte Ltd (PAC) with the person	Promoter	ARCC30554

Signature of the Authorised Signatory



Place:

Date: 1<sup>st</sup> April, 2016


Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

This message is not intended for general use and may contain information which is sensitive, confidential or restricted. If you are not the authorised recipient, you are hereby notified that any use, copying, or distribution of this message, its contents or attachments is strictly prohibited.



gsk.com | Twitter | YouTube | Facebook | LinkedIn

Tel +442080474504  
 Email paul.williamson@gsk.com  
 960 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom

Paul Williamson  
 Corporate Secretary

Kindly take on record and confirm the same.

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskaylab Limited	58,80,000	6.94
3	Burrghs Wellcome International Limited	33,60,000	3.97
4	Glaxosmithkline Pte Ltd	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
	<b>Total</b>	<b>6,36,27,262</b>	<b>76.00</b>

Please find attached Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

Dear Sir,

From: Paul Williamson  
 Sent: Monday, April 04, 2016 5:17 PM  
 To: takeover@nse.co.in  
 CC: Ajay Nadkarni; Amita Patel  
 Subject: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

From: Ajay Nadkarni  
 Sent: Monday, April 04, 2016 5:24 PM  
 To: Rohan Mota  
 Subject: FW: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

Rohan Mota

Pte - 2016 - NSE

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE
3. Particulars of the shareholder(s):	
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC, or	GlaxoSmithKline Pte Ltd
b. Name(s) of promoter(s), member of the promoter group and PAC with him,	
4. Particulars of the shareholding of person(s) mentioned at (3) above	
As on March 31 <sup>st</sup> of the year 2016, holding of:	
a) Shares	2,06,09,774
b) Voting Rights (otherwise than by shares)	24.33
c) Warrants,	-
d) Convertible Securities	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-
Total	2,06,09,774
As on March 31 <sup>st</sup> of the year 2016, holding of:	
a) Shares	24.33
b) Voting Rights (otherwise than by shares)	24.33
c) Warrants,	-
d) Convertible Securities	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-
Total	24.33

Part-B\*\*

Name of the Target Company:

Name(s) of the person and Persons Acting in Concert	GlaxoSmithKline Plc Ltd
(PAC) with the person	
Whether the person belongs to Promoter/Promoter group	Promoter
PAN of the person and PACs	AAccc3055g

Signature of the Authorised Signatory

Place:

Date: 1st April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):	<p>a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.</p> <p>b. Name(s) of promoter(s), member of the promoter group and PAC with him.</p> <p>4. Particulars of the shareholding of person(s) mentioned at (3) above</p>		
Number of shares	% w.r.t. total share voting capital	share/voting capital wherever applicable (*)	% of total diluted share/voting capital of TC
As on March 31 <sup>st</sup> of the year 2016, holding of:	3,192,238	3.77	3.77
a) Shares	3,192,238	3.77	3.77
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
<b>Total</b>	<b>3,192,238</b>	<b>3.77</b>	<b>3.77</b>

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

regulation 30(1) is required.

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under

Note:

Date: 1<sup>st</sup> April, 2016

Place: Mauritius


Signature of the Authorised Signatory



Name(s) of the person and Persons Acting in Concert Promoter/Promoter group	Whether the person belongs to	PAN of the person and PACs
Castleton Investment Ltd	Promoter	HAECG4327P
(PAC) with the person		

Name of the Target Company:





gsk.com | Twitter | YouTube | Facebook | Flickr

Tel +442080474504  
Email paul.williamson@gsk.com  
900 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom  
GSK

Regards  
Paul Williamson  
Assistant Company Secretary - Group Operations  
Corporate Secretary

Kindly take on record and confirm the same.

Sl no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	EskaLab Limited	58,80,000	6.94
3	Burroughs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd	2,06,08,774	24.33
5	Castleon Investment Limited	31,92,238	3.77
	<b>Total</b>	<b>6,36,27,262</b>	<b>75.00</b>

Please find attached Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Dear Sir,

From: Paul Williamson  
Sent: Friday, April 01, 2016 6:41 PM  
To: cotb.regulations@bseindia.com  
Cc: Ajay Nadkarni; Amita Patel  
Subject: Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Ajay  
Regards

FYI and file. Please confirm with BSE they have received this email.

Attachments:  
Subject: FV; Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited  
From: Ajay Nadkarni  
Sent: Monday, April 04, 2016 2:02 PM  
To: Anand Joshi; Rohan Mota  
A\Disclosures under Reg 30(1) 30(2) of SEBI Reg 2011 (2).pdf

Rohan Mota

2016

pt. 2016 - BCE

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited			
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE			
3. Particulars of the shareholder(s):	<p>a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.</p> <p>b. Name(s) of promoter(s), member of the promoter group and PAC with him.</p> <p>4. Particulars of the shareholding of person(s) mentioned at (3) above</p>			
As on March 31 <sup>st</sup> of the year 2016, holding of:	a) Shares	b) Voting Rights (otherwise than by shares)	c) Warrants, Convertible Securities	d) Any other instrument that would entitle the holder to receive shares in the TC.
Total	2,06,09,774	2,06,09,774	24.33	24.33

Part-A- Details of Shareholding

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity-shares of the TC.


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 1<sup>st</sup> April, 2016

Place:

Signature of the Authorised Signatory



Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	AACCC3055g

Name of the Target Company:

Part-B\*\*

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):	Castleton Investment Ltd		
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC, or b. Name(s) of promoter(s), member of the promoter group and PAC with him.			
4. Particulars of the shareholding of person(s) mentioned at (3) above	% of total share/voting capital diluted share/voting capital of TC (*)	% w.r.t. total share/voting capital whenever applicable	Number of shares
As on March 31 <sup>st</sup> of the year 2016, holding of:	3.77	3.77	3,192,238
Total	3.77	3.77	3,192,238
a) Shares	3.77		
b) Voting Rights (otherwise than by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC.			

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted sharevoting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 1<sup>st</sup> April, 2016

Place: Mauritius

Signature of the Authorized Signatory



Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Castleton Investment Ltd	Promoter	AHEC64321P

Name of the Target Company:

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	2. Name(s) of the stock exchange(s) where the shares of the TC are listed	3. Particulars of the shareholder(s)	4. Particulars of the shareholding of person(s) mentioned at (3) above	As of March 31st of the year, holding of:	Total
GlaxoSmithKline Pharmaceuticals Limited	Bombay Stock Exchange: BSE National Stock Exchange: NSE	a) Name of person(s) together with total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name(s) of promoter(s), member of the promoter group and PAC with him.	Number of shares % of total share capital % of total diluted capital	a) Shares b) Rights (with voting rights) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	
		Glaxo Group Limited GlaxoSmithKline Plc Limited Esjayab Limited Burroughs Wellcome International Limited Cartledge Investment Limited		75% 75% 84703017 84703017	

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Signature of the Authorized Signatory:

For and on behalf of  
The Wellcome Foundation Limited  
Date: 1 April 2014  
Place: England

CIL - Jomr - 2014 - to company

Digitale Identity Number  
L242954192497L0901163  
Email to: info@csk.com  
Web site address: www.csk.com

Encl:

Ajay Narkari  
General Manager - Administration  
& Company Secretary

GlaxoSmithKline Pharmaceuticals Limited

Yours faithfully

Thanking you,

We hope the same is in order.

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Welcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2014.

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of shares and Takeovers) Regulations, 2011

Dear Sir,

NATIONAL STOCK EXCHANGE,  
EXCHANGE PLAZA, 6<sup>TH</sup> FLOOR,  
PLOT No. C/1, G BLOCK,  
BANDRA-KURLA COMPLEX,  
BANDRA (EAST), MUMBAI  
400061

4<sup>th</sup> April 2014

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: CSK House,  
Dr. Annie Besant Road,  
Worli, Mumbai - 400030.  
Tel: +91 22 2495 9595  
Fax: +91 22 2495 9494

GlaxoSmithKline



NSE

CIL 30mt - 2014 - to NSE





Corporate Identity Number  
L24329MH1924PL000133  
Email: [skh@skh.com](mailto:skh@skh.com)  
Web site address: [www.pak-india.com](http://www.pak-india.com)

Encl:

Ajay Nadekar  
General Manager - Administration  
& Company Secretary

*(Signature)*

Yours faithfully  
GlaxoSmithKline Pharmaceuticals Limited

Thanking you,

We hope the same is in order.

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith a consolidated confirmation for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskayab Limited, Burroughs Wellcome International Limited and Caelaton Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2014.


SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

BOMBAY STOCK EXCHANGE LIMITED  
PHIROZE JEEJEEBHAY TOWERS  
DALAL STREET  
MUMBAI  
400001

4<sup>th</sup> April 2014

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Amte Resant Road,  
Ward, Mumbai - 400030.  
Tel: +91 22 2495 9595  
Fax: +91 22 2495 9194






1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited	
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3	Particulars of the shareholder(s) :		
a.	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	or	
		Name(s) of promoter(s), member of the promoter group and PAC with him.	
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	As of March 31st of the year, holding of:
		Number of share/voting share/voting diluted share/voting capital share/voting share/voting capital of TC (%)	
		% w.r.t. total % of total	
		3.77	3.77
		3192238	3192238
		3.77	3.77
		3.77	3.77
			Total


Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1



21.03.2017 to 16:01



Part-B\*\*

Name of the Target Company: GlaxoSmithKline Pharmaceuticals Limited

Names(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	

Signature of the Authorised Signatory

*[Handwritten Signature]*

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Corporate Identity Number  
L24239MH1924PLC001194  
Email (d.rajhu@glaxo.com)  
Web site address: www.gsk.com

Encl:

Ajay Nadkarni  
General Manager - Administration  
& Company Secretary

*Ajay Nadkarni*

Yours faithfully  
GlaxoSmithKline Pharmaceuticals Limited

Thanking you,

We hope the same is in order.

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleion Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2015.

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

NATIONAL STOCK EXCHANGE,  
EXCHANGE PLAZA, 5<sup>TH</sup> FLOOR,  
PLOT No. C/1, G BLOCK,  
BANDRA KURLA COMPLEX,  
BANDRA (EAST), MUMBAI  
400031


9<sup>th</sup> April 2015

GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Amte Besant Road,  
Worli, Mumbai - 400030.  
Tel: +91 22 2495 9505  
Fax: +91 22 2495 9494

GlaxoSmithKline







Part-B\*\*

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	-

Signature of the Authorised Signatory

*[Handwritten Signature]*

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठान और विनिमय बोर्ड**

1 Name of the Target Company (TC)		GlaxoSmithKline Pharmaceuticals Limited	
2 Name(s) of the stock exchange(s) where the shares of the TC are listed		Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3 Particulars of the shareholder(s) :			
a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instruments that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC		GlaxoSmithKline Pre Ltd.	
b. Name(s) of promoter(s), member of the promoter group and PAC with him.			
4 Particulars of the shareholding of person(s) mentioned at (3) above		Number of shares	
As of March 31st of the year, holding of:		share/voting capital share/voting diluted % of total	
a) Shares		24.33	
b) Voting Rights (otherwise than by shares)		24.33	
c) Warrants,			
d) Convertible Securities			
d) Any other instrument that would entitle the holder to receive shares in the TC.		24.33	
Total		24.33	

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1

**Securities and Exchange Board of India**  
**भारतीय प्रतिष्ठान और विनिमय बोर्ड**

770 APR 2015



(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 2 April 2017

Place: Singapore

Signature of the Authorized Signatory

Name(s) of the person and Persons Acting in Concert	GlaxoSmithKline Pte Ltd
(PAC) with the person	Promoter
Whether the person belongs to Promoter / Promoter group	
PAN of the person and PACs	

GlaxoSmithKline Pharmaceuticals Limited

Name of the Target Company

Part-B\*\*

Corporate Identity Number  
L24236MH1924PLC00191  
Email id: sekus@gsk.com  
Web site address: www.gsk-india.com

Encl:  
Ajay Nadekarni  
General Manager - Administration  
& Company Secretary.  
*Ajay Nadekarni*  
GlaxoSmithKline Pharmaceuticals Limited  
Yours faithfully  
Thanking you,

We hope the same is in order.  
Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Caetleon Investment Limited in respect of their shareholding in our Company as on 31<sup>st</sup> March 2015.

SECURITIES & EXCHANGE BOARD OF INDIA  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

BOMBAY STOCK EXCHANGE LIMITED  
PHIROZE JEEJEBHOY TOWERS  
DALAL STREET  
MUMBAI  
400001

6<sup>th</sup> April 2015  
Tel: +91-22 2495 9595  
Fax: +91 22 2495 9494  
GlaxoSmithKline  
Pharmaceuticals Limited  
Regd. Office: GSK House,  
Dr. Amle Besant Road,  
Vashi, Mumbai - 400030.

GlaxoSmithKline




2015


1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) :	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share/voting capital wherever applicable	diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:		3192238	3.77	3.77
a) Shares				
b) Voting rights (otherwise than by shares)				
c) Warrants,				
d) Convertible Securities				
d) Any other instrument that would entitle the holder to receive shares in the TC.				
Total		3192238	3.77	3.77

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(2) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1





Part-B\*\*

Name of the Target Company: GlaxoSmithKline Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
Castleton Investment Limited	Promoter	

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

<sup>1</sup> In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

<sup>(\*)</sup> Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

<sup>(\*\*)</sup> Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

**SEBI** भारतीय प्रतिष्ठान और विनिमय बोर्ड  
**Securities and Exchange Board of India**

1	Name of the Target Company (TC)	Glaxosmithkline Pharmaceuticals Limited	
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3	Particulars of the shareholders :		
a.	Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	Glaxosmithkline Pre Ltd	
b.	Name(s) of promoter(s), member of the promoter group and PAC with him.		
Particulars of the shareholding of person(s) mentioned at (3) above			
As of March 31st of the year, holding of:			
a)	Shares	20609774	24.33
b)	Voting Rights (otherwise than by shares)		
c)	Warrants		
d)	Convertible Securities		
d)	Any other instrument that would entitle the holder to receive shares in the TC.		
Total		20609774	24.33

Part-A: Details of Shareholding

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ANNEXURE-1

**SEBI** भारतीय प्रतिष्ठान और विनिमय बोर्ड  
**Securities and Exchange Board of India**

SEBI  
 27th APR 2015  
 SEBI


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.  
 (a) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.  
 (\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Note:

Date: 2 April 2015

Place: Singapore

Signature of the Authorized Signatory



Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter / Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd	Promoter	

Name of the Target Company

GlaxoSmithKline Pharmaceuticals Limited

Part-B\*\*

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):	Castleton Investment Ltd		
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.		Number of shares	
4. Particulars of the shareholding of person(s) mentioned at (3) above	% of total diluted share/voting capital of TC (*)	% w.r.t. total share /voting capital wherever applicable	Number of shares
As on March 31 <sup>st</sup> of the year 2016, holding of:	3.77	3.77	3,192,238
a) Shares	3.77	-	-
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3.77	3.77	3,192,238

GLC - 2016 - re company

(\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 1<sup>st</sup> April, 2016

Place: Mauritius

Signature of the Authorised Signatory



Names) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Castleton Investment Ltd	Promoter	AAECG4321P

Name of the Target Company:



This message is not intended for general use and may contain information which is sensitive, confidential or restricted. If you are not the authorized recipient, you are hereby notified that any use, copying, or distribution of this message, its contents or attachments is strictly prohibited.



gsk.com | Twitter | YouTube | Facebook | Flickr

960 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom  
 Email [pauly.williamson@gsk.com](mailto:pauly.williamson@gsk.com)  
 Tel +442080474504

Paul Williamson  
 Corporate Secretary

Kindly take on record and confirm the same.

Sr no	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,250	35.99
2	Eskayab Limited	58,80,000	6.94
3	Burroughs Wellcome International Limited	33,60,000	3.97
4	Glaxosmithkline Pvt Ltd	2,06,09,774	24.33
5	Castleton Investment Limited	31,92,238	3.77
	<b>Total</b>	<b>6,36,27,262</b>	<b>76.00</b>

As find attached Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

From: Paul Williamson  
 Sent: Monday, April 04, 2016 5:17 PM  
 To: [takeover@nse.co.in](mailto:takeover@nse.co.in)  
 Cc: Ajay Nadkarni; Anita Patel  
 Subject: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

From: Ajay Nadkarni  
 Sent: Monday, April 04, 2016 5:24 PM  
 To: Rohan Mota  
 Subject: FW: Promoters Disclosure required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for Glaxosmithkline Pharmaceuticals Limited

Rohan Mota

21-2016 - NSE

1. Name of the Target Company (TC)		2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	
GlaxoSmithKline Pharmaceuticals Limited		Bombay Stock Exchange, BSE National Stock Exchange, NSE	
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.			
4. Particulars of the shareholding of person(s) mentioned at (3) above			
% of total diluted share/voting capital of TC (*)	Number of shares	% w.r.t. total share/voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
24.33	2,06,09,774	24.33	24.33
As on March 31 <sup>st</sup> of the year 2016, holding of:			
a) Shares			
b) Voting Rights (otherwise than by shares)			
c) Warrants			
d) Convertible Securities			
e) Any other instrument that would entitle the holder to receive shares in the TC			
Total		2,06,09,774	
		24.33	
		24.33	

Part-A- Details of Shareholding

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Note: 1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.


(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Date: 1<sup>st</sup> April, 2016

Place:

Signature of the Authorised Signatory



Name(s) of the person and Persons Acting in Concert	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd (PAC) with the person	Promoter	AHCCC30554

Name of the Target Company:

Part-B\*\*

Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	% of total diluted share/voting capital of TC (*)	% w.r.t. total share/voting capital whomever applicable	Number of shares
As on March 31 <sup>st</sup> of the year 2016, holding of:	a) Shares	3.77	3,192,238
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	3.77	3.77	3,192,238

(\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 1<sup>st</sup> April, 2016


Place: Mauritius


Signature of the Authorised Signatory



Names(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Castleton Investment Ltd	Promoter	BAECCG4321P

Name of the Target Company:





GSK.com | Twitter | YouTube | Facebook | Flickr

GSK  
 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom  
 Email: paul.williamson@gsk.com  
 Tel: +442080474604

Regards  
 Paul Williamson  
 Assistant Company Secretary - Group Operations  
 Corporate Secretary

Kindly take on record and confirm the same.

Sr. no.	Particulars	No of Shares	Percentage
1	Glaxo Group Limited	3,04,85,260	36.99
2	Eskayab Limited	58,80,000	6.94
3	Burroughs Wellcome International Limited	33,60,000	3.97
4	GlaxoSmithKline Pte Ltd		
5	Castleton Investment Limited	2,06,09,774	24.33
Total		6,35,27,262	3.77
			75.00

Please find attached Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Dear Sir,

From: Paul Williamson  
 Sent: Friday, April 01, 2016 6:41 PM  
 To: corporations@bseindia.com  
 Cc: Ajay Nadkarni; Amita Patel  
 Subject: Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited

Regards  
 Ajay  
 FYI and file. Please confirm with BSE they have received this email.

Attachments:  
 From: Rohan Mota  
 To: Ajay Nadkarni  
 Sent: Monday, April 04, 2016 2:02 PM  
 Subject: FW: Promoters Disclosure (details mentioned below) required under Regulation 30(1) & 30(2) of SEBI Takeover Regulations, 2011 for GlaxoSmithKline Pharmaceuticals Limited  
 And Josh; Rohan Mota  
 AD disclosures under Reg 30(1) 30(2) of SEBI Reg 2011 (2).pdf

2016

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A- Details of Shareholding

<p>1. Name of the Target Company (TC) GlaxoSmithKline Pharmaceuticals Limited</p>	<p>2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed Bombay Stock Exchange, BSE National Stock Exchange, NSE</p>	<p>3. Particulars of the shareholder(s): a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC, or b. Name(s) of promoter(s), member of the promoter group and PAC with him. GlaxoSmithKline Pte Ltd</p>	<p>4. Particulars of the shareholding of person(s) mentioned at (3) above Number of shares % w.r.t. total share / voting capital wherever applicable share/voting capital of TC diluted (%)</p>	<p>As on March 31<sup>st</sup> of the year 2016, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.</p>	<p>2,06,09,774</p>	<p>24.33</p>	<p>24.33</p>	<p>Total</p>
---	--	--	---	--	--------------------	--------------	--------------	--------------

(\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.


1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Note:

Date: 1<sup>st</sup> April, 2016

Place:

Signature of the Authorised Signatory



Name(s) of the person and Persons Acting in Concert	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
GlaxoSmithKline Pte Ltd (PAC) with the person	Promoter	AHCC3055G

Name of the Target Company:

Part-B




Part-A- Details of Shareholding

1. Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	Bombay Stock Exchange, BSE National Stock Exchange, NSE		
3. Particulars of the shareholder(s):			
a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Ltd		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share voting capital wherever applicable	As on March 31 <sup>st</sup> of the year 2016, holding of:
a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	3,192,238	3.77	3.77
Total	3,192,238	3.77	3.77

Name(s) of the person and Persons Acting in Concert	Whether the person belongs to Promoter/Promoter group	PAN of the person and PACs
Castleon Investment Ltd.	Promoter	BAEC64321P

Signature of the Authorised Signatory



Place: Mauritius

Date: 1<sup>st</sup> April, 2016

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.